Cervical Cancer Diagnostic Tests Market, By Test Type, By Age Group, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Cervical cancer, or cancer of the cervix, begins on the surface of your cervix. It happens when the cells on your cervix begin to change to precancerous cells. There are two main types of cancer of the cervix: squamous cell carcinomas and adenocarcinomas. About 80% to 90% of cervical cancers are squamous cell carcinomas, while 10% to 20% are adenocarcinomas. Watery or bloody vaginal discharge that may be heavy and can have a foul odor, vaginal bleeding after intercourse, between menstrual periods or after menopause and menstrual periods may be heavier and last longer than normal are some sign and symptoms of stage 1 cervical cancer. Most cervical cancers are caused by the virus HPV, a sexually transmitted infection. Human papillomavirus (HPV) spreads through sexual contact (anal, oral or vaginal) and can lead to cancer. Most people will get HPV at some point in their lives and not realize it because their bodies fight the infection. Receiving regular gynecological exams, getting Pap tests and practicing safe sex are the most important steps that you can take toward the prevention of cervical cancer. Surgery, radiation and chemotherapy are the main treatments for cervical cancer. Pap smear, colposcopy, and endocervical curettage (ECC) procedures are performed for the diagnosis of cervical cancer. Increasing awareness regarding cervical cancer in emerging economies and increasing funding for research and development in diagnosis of cervical cancer are expected to drive growth of the market during the forecast period.

Market Dynamics

Over the projected period, the global market for cervical cancer diagnostic tests is anticipated to increase due to the rising incidence of the disease, the high frequency of patients infected with the human papillomavirus (HPV), and the rising number of teenage sex experiences. For instance, in February 2022, according to the World Health Organization (WHO), Cervical cancer is the fourth most common cancer among women globally, with an estimated 604 000 new cases and 342 000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries such as Afghanistan, Bangladesh, India, China, etc.

Key features of the study:

• This report provides in-depth analysis of the global cervical cancer diagnostic tests market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cervical cancer diagnostic tests market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Guided Therapeutics, Inc., Abbott, Beckman Coulter, Inc., BD (Becton, Dickinson and Company), F. Hoffmann-La Roche Ltd, Bio Farma, Hologic, Inc., Oncgnostics GmbH, AstraZeneca, MobileODT, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., DYSIS Medical Inc., The Cooper Companies Inc., Danaher, Quest Diagnostics, Arbor Vita Corporation, and Zilico.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global cervical cancer diagnostic tests market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts :

• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cervical cancer diagnostic tests market.

Detailed Segmentation:

Global Cervical Cancer Diagnostic Tests Market, By Test Type:

• Pap Smear Test
• Colposcopy Test
• Endocervical curettage Test
• HPV Test

Global Cervical Cancer Diagnostic Tests Market, By Age Group:

• Age 20-40
• Age above 40

Global Cervical Cancer Diagnostic Tests Market, By Region:

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa

Company Profiles

• Guided Therapeutics, Inc
• Abbott
• Beckman Coulter, Inc.
• BD (Becton, Dickinson and Company)
• Hoffmann-La Roche Ltd
• Bio Farma
• FinVector Vision Therapies
• Hologic, Inc.
• Oncgnostics GmbH
• AstraZeneca
• MobileODT
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• DYSIS Medical Inc.
• The Cooper Companies Inc.
• Danaher
• Quest Diagnostics
• Arbor Vita Corporation
• Zilico